Fierce Pharma
OCTOBER 9, 2023
Following similar initiatives to bolster mRNA vaccine production and access in Africa, the Bill & Melinda Gates Foundation is providing new funding to a clutch of drugmakers. | Following similar initiatives to bolster mRNA vaccine production and access in Africa, the Bill & Melinda Gates Foundation is providing new funding to a clutch of drugmakers.
MedCity News
OCTOBER 9, 2023
The ultimate challenge for the broader adoption of AI in medical imaging remains the same: demonstrating to healthcare institutions that it provides a clear ROI.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
OCTOBER 9, 2023
GSK has forged a partnership with vaccine powerhouse Chongqing | GSK has forged a partnership with vaccine powerhouse Chongqing Zhifei Biological Products to distribute Shingrix in China. Zhifei will pay £2.5 billion ($3.05 billion) for exclusive rights to distribute the shingles shot in China from 2024 through 2026. The deal could be a precursor to similar arrangement between the companies for GSK’s new respiratory syncytial virus (RSV) vaccine Arexvy, the London-based drugmaker said.
MedCity News
OCTOBER 9, 2023
Endless digital health solutions have emerged over the last few years. But eventually, they’ll have to consolidate — and that’s part of the cycle, investors said during a panel discussion on Sunday.
Fierce Pharma
OCTOBER 9, 2023
Marketers operating in every sector are seeking ways to offer personalized, high-quality experiences to their target audiences. | How much influence will AI exert over pharma marketing? Is it a silver bullet solution to productivity and personalization challenges? Fingerpaint Group’s Paul Hagopian sits down with Fierce Pharma to discuss what has become a hotly contested topic.
MedCity News
OCTOBER 9, 2023
The opening day of the HLTH 2023 event offered a surprising announcement from venture capital firm General Catalyst. Weight Watchers CEO called for a change in how we talk about obesity. ENGAGE at HLTH offered compelling discussions around retail health, prescription drug prices and investment trends.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
OCTOBER 9, 2023
Healthcare technology experts have confidence that the industry will put the right guardrails up around LLMs as it continues to develop and deploy these AI tools, they said Sunday during a panel discussion at Engage at HLTH.
Fierce Pharma
OCTOBER 9, 2023
The way we consume and engage with content is changing all the time. | How can marketers leverage AI to make sense of the masses of data they have access to? Chris Paquette, Founder and CEO of DeepIntent, explores the issues of fragmentation and outlines some of the tools designed to overcome it.
MedCity News
OCTOBER 9, 2023
Acquiring Mirati Therapeutics brings Bristol Myers Squibb Krazati, one of two FDA-approved therapies addressing a KRAS cancer mutation. The deal comes as BMS looks to add revenue-generating products as patent expirations loom for several of its cancer products.
Fierce Pharma
OCTOBER 9, 2023
Roche preps for filings after subcutaneous Ocrevus matches up to IV formulation in phase 3 study zbecker Mon, 10/09/2023 - 18:07
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
MedCity News
OCTOBER 9, 2023
Despite an affirmative FDA advisory committee vote, the agency declined to approve Alnylam Pharmaceuticals’ Onpattro for treating the heart complications caused by a rare, inherited protein disorder. But Alnylam has other drugs candidates for the disease, including one expected to post Phase 3 data in the first half of 2024.
Fierce Pharma
OCTOBER 9, 2023
The pharmaceutical and biopharmaceutical industries are currently underutilizing their manufacturing data, with a significant portion of the collected data either non-actionable or of insufficient | Discover how implementing digital continued process verification (CPV) elevates product quality assurance and drives operational excellence.
MedCity News
OCTOBER 9, 2023
By combining AI with human expertise and oversight, we have the potential to revolutionize the clinical trial process—and most importantly, extend and save lives.
Fierce Pharma
OCTOBER 9, 2023
Dorothy Gemmel, the Chief Commercial Officer for manufacturer solutions business within GoodRx, identifies two exciting opportunities in pharma marketing today: personalization and partnerships. | GoodRx connects patients with pharmaceutical brands through personalization, data utilization, and strategic partnerships - necessities in modern pharma marketing.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
European Pharmaceutical Review
OCTOBER 9, 2023
A new drug, part of a class of chemicals called potassium-channel openers, has demonstrated potential in offering relief to patients with focal epilepsy. Key data from a clinical trial, published in a report in JAMA Neurology, has revealed that adding the drug XEN1101 to a patient’s current antiseizure treatments saw a 33 percent to 53 percent drop in monthly seizures, depending on dose.
Pharmaceutical Technology
OCTOBER 9, 2023
GSK and Chongqing Zhifei have signed an exclusive agreement for co-promoting the former’s shingles vaccine, Shingrix, in China.
European Pharmaceutical Review
OCTOBER 9, 2023
Bristol Myers Squibb ( BMS ) has agreed to acquire Mirati Therapeutics for a total of $4.8 billion. This merger deal entitles BMS to add KRAZATI (adagrasib), a best-in-class KRAS G12C inhibitor to its portfolio. The medicine is approved in the US for advanced KRAS G12C -mutated non-small cell lung cancer (NSCLC) in patients who have received at least one prior systemic treatment.
Pharmaceutical Technology
OCTOBER 9, 2023
Diabetes researchers oppose the regulation of islet transplantation as a biologic, following the approval of CellTrans’ Lantidra.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
European Pharmaceutical Review
OCTOBER 9, 2023
MSD’s WELIREG ® (belzutifan) has been accepted for use within NHS Scotland in adults who have von Hippel-Lindau (VHL) disease. This decision by the Scottish Medicines Consortium (SMC) relates to these patients who require therapy for VHL-associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumours (pNETs), and for whom localised procedures are unsuitable or undesirable.
PharmExec
OCTOBER 9, 2023
Cosentyx is the first intravenous formulation interleukin-17A antagonist to focus on disease.
PharmaTimes
OCTOBER 9, 2023
The study will offer new insights into the immune system's response to iGAS - News - PharmaTimes
Healthcare Success
OCTOBER 9, 2023
Healthcare consumers demand better, more personalized experiences at every touchpoint. According to Google, approximately 77% of people use search engines to start their patient journey. Listen to the podcast: So, it makes sense for healthcare businesses to focus their attention on their websites, landing pages, and paid search campaigns. But what happens after your ads have captured their attention—especially with a PPC or display ad?
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
PharmaTimes
OCTOBER 9, 2023
The agreement builds on the companies’s existing partnership - News - PharmaTimes
PharmExec
OCTOBER 9, 2023
Supporters include Novartis Venture Fund, Brandon Capital, and more.
PharmaVoice
OCTOBER 9, 2023
Tune Therapeutics is hoping to overcome the pitfalls of CRISPR-style treatments with epigenetic editing.
Legacy MEDSearch
OCTOBER 9, 2023
HistoSonics ® , ( www.histosonics.com ), the manufacturer of the Edison ® System and novel histotripsy therapy platforms, announced today the marketing authorization of its “Breakthrough” platform via the U.S. Food and Drug Administration’s (FDA) De Novo Classification Request process, a rigorous pre-market review pathway for medical devices with no existing predicate.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
PharmaTech
OCTOBER 9, 2023
Laks Pernenkil, principal and practice leader, US Life Sciences Product & Supply Operations, Deloitte, discusses the impact that digitalization is having on data generation and data integrity in bio/pharma manufacturing.
PM360
OCTOBER 9, 2023
Populus Media Inc., a pioneer in digital pharma marketing and patient acquisition solutions leveraging virtual care, today announced that the company has re-branded as Populus Health Technologies concurrent with the official launch of HCP Reach , its physician-facing virtual care channel. The rebranding reflects the company’s broader data-driven product line built to empower pharmaceutical brands with the tools to bolster brand awareness and leverage new virtual tactics for acquiring, activating
Curzon Consulting
OCTOBER 9, 2023
Consultant Contact me Preetesh is a management consultant and technology expert with over 6 years of experience driving digital transformation and innovation initiatives at global corporations. He began his career at Cisco Systems, where he managed the development and delivery of smart manufacturing solutions. By spearheading the global synchronisation of smart manufacturing platforms, Preetesh enabled significant cost savings through operational efficiency.
Pharmaceutical Technology
OCTOBER 9, 2023
Semaglutide: compared to key European markets, its higher price and that of other diabetes/obesity drugs in the US could impact on healthcare
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
Expert insights. Personalized for you.
339 
Let's personalize your content